as of 11-17-2026 12:59pm EST
Intelligent Bio Solutions Inc is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its current active product is the Intelligent Fingerprinting Platform, consisting of a proprietary portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its flagship product, the Intelligent Fingerprinting Drug Screening System, is a two-part system of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Company operates in APAC, the UK, the Americas, and the rest of the world, with maximum revenue from the United Kingdom.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 6.5M | IPO Year: | 2019 |
| Target Price: | N/A | AVG Volume (30 days): | 36.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.86 | EPS Growth: | -322.00 |
| 52 Week Low/High: | $0.54 - $24.90 | Next Earning Date: | 11-10-2026 |
| Revenue: | $1,980,484 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 44.72% | Revenue Growth (next year): | 44.26% |
| P/E Ratio: | -1.78 | Index: | N/A |
| Free Cash Flow: | -12052953.0 | FCF Growth: | N/A |
SEC 8-K filings with transcript text
Nov 10, 2026 · 40% conf.
1D
-1.17%
$2.21
Act: -7.11%
5D
-11.07%
$1.99
20D
+75.52%
$3.93
2 ex99-1.htm
Exhibit 99.1
Press Release
Intelligent Bio Solutions Reports Record Fiscal First Quarter 2027 Revenue of $1.39 Million, Marking Sixth Consecutive Quarter of Year-Over-Year Growth
Revenue up 25% year-over-year and 21% sequentially, marking third consecutive quarter above $1 million
Higher-margin
cartridge sales grew 32% year-over-year and 35% sequentially, representing 61% of total revenue
Gross profit margin expanded to 54.5%, up from 46.6% in the prior-year quarter
Company submitted its FDA 510(k) premarket notification during the quarter, a key step toward planned U.S. market entry
NEW YORK, November 10, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2026.
“Fiscal first quarter revenue was the highest quarterly revenue in our Company’s history,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “Each reader draws on a recurring supply of higher-margin cartridges, which is driving most of our revenue growth. Our business continues to scale with improving unit economics, including expanding gross profit margins driven by manufacturing efficiencies and a higher share of revenue from higher-margin cartridge consumables.”
Mr. Simeonidis continued, “In September, we submitted our 510(k) premarket notification to the FDA for the Intelligent Fingerprinting Drug Screening System, the culmination of the clinical program we executed throughout 2026 and a key step toward our planned entry into the multi-billion-dollar U.S. drug screening market. Going forward, we will continue to invest in the clinical and regulatory work behind our 510(k) submission while maintaining discipline across the rest of the business.”
Product Revenue Breakdown
Three Months Ended September 30, 2026 (Q1 Fiscal 2027):
●Total revenue of $1.39 million, up 25% year-over-year and 21% sequentially
●Cartridge sales of $845,583, up 32% year-over-year and 35% sequentially, representing 61% of Q1 revenue
Page 1 of 5
●Other sales of $281,253, up 52% year-over-year, representing 20% of Q1 revenue
●Gross profit of $758,004, up 46% year-over-year, with gross profit margin of 54.5%, up from 46.6% in the same period the year prior
●Cash and cash equivalents of $5.93 million at September 30, 2026, compared to $3.99 million at June 30, 2026
Fiscal First Quarter 2027 and Subsequent Highlights
●Record quarterly revenue: Revenue of $1,391,835 surpassed the Company’s prior quarterly record of $1,145,802, set in the fourth quarter of fiscal 2026, and marked the third consecutive quarter of sequential revenue growth and the third consecutive quarter above $1 million.
●Cartridge consumables driving growth: Cartridge sales accounted for 73% of the $280,038 year-over-year increase in total revenue and grew to 61% of quarterly revenue, up from 58% a year ago.
●Gross profit margin above 54%: Gross profit margin of 54.5% improved approximately 790 basis points year-over-year, reflecting manufacturing efficiencies and a growing share of higher-margin cartridge sales.
510(k) submitted: On September 9, 2026, the Company submitted its 510(k) premarket notification to the FDA, seeking clearance of the Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine. The submission included a method comparison study that demonstrated accuracy above 98%, sensitivity above 94%, and specificity of 100% across three independent U.S. clinical sites.
●510(k) clinical program completed: During the quarter, the Company completed precision testing, interference, usability, and method comparison studies, and resolved all cybersecurity review items, finalizing the body of clinical evidence supporting its submission.
13485:2016 recertification: The Company’s Intelligent Fingerprinting Drug Screening business was recertified to the ISO 13485:2016 quality management system standard by the British Standards Institution, supporting alignment with the FDA’s amended Quality Management System Regulation.
●Customer and installed base growth: 516 active customer accounts as of September 30, 2026, including 27 new accounts added during the quarter, with a reader installed base of 1,978 units.
The fiscal first quarter extended INBS’s consistent run of growth, with the installed base built through prior reader placements continuing to drive recurring, higher-margin cartridge demand. With its 510(k) submission complete, record quarterly revenue, and expanding gross profit margins, management believes the Company is well-positioned to continue its growth through fiscal 2027 as it pursues its planned entry into the multi-billion-dollar U.S. drug screening market.
Page 2 of 5
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (Nasdaq: INBS) is a
Aug 19, 2026 · 97% conf.
1D
+9.59%
$2.93
Act: -0.75%
5D
+13.42%
$3.03
20D
+3.51%
$2.76
2 ex99-1.htm
Exhibit 99.1
Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth
Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units
Full year gross profit margin expanded to 48.63%, up 778 basis points year-over-year
502 active customers as of June 30, 2026, reflecting continued commercial momentum across safety-critical industries
Company made substantial progress toward FDA clearance and planned market expansion during the year
NEW YORK, August 19, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the full year ended June 30, 2026, and provided a business update.
“Fiscal 2026 was a year of clear, compounding progress across every aspect of our business,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “We delivered record annual revenue of $4.2 million, a 38% increase year-over-year, driven by a 22% expansion in our reader installed base and a 35% increase in consumable cartridges. Our razor-razorblade model is gaining scale, with hardware placements generating the installed base and growing consumable utilization delivering recurring revenue. Entering fiscal 2027, we are focused on three priorities: sustaining the operational improvements driving gross margin expansion, continuing to accelerate commercial growth, and advancing our FDA regulatory program toward planned U.S. market entry. To that end, we have completed all clinical data collection across our FDA 510(k) clinical study program. Analysis of collected data is underway, and we remain on track for our FDA submission.”
“The financial results for fiscal 2026 reflect a business that is scaling with improving unit economics,” said Spiro Sakiris, CFO at Intelligent Bio Solutions. “Full-year gross profit grew 64% to $2.05 million and gross margin expanded 778 basis points to 48.63%. These improvements are a result of our transition to Syrma Johari as a high-quality, lower-cost manufacturing partner, an optimized product mix weighted toward higher-margin cartridge consumables, and the operational leverage that comes from growing volumes across a more efficient production base. Our sustained investment in marketing, sales, product awareness, and customer support has been the direct commercial driver behind our 38% revenue growth and the expanding utilization we are seeing across our installed base.”
Full Year Fiscal 2026 Financial Highlights
●Total revenue of $4,215,175, up 38% year-over-year from $3,052,532.
●Revenue increase of $1,162,643 year-over-year.
●Gross profit of $2,049,994, up 64% year-over-year from $1,246,859.
●Gross profit margin of 48.63%, up from 40.85% - an improvement of 778 basis points.
●Reader installed base of 1,886 units as of June 30, 2026, up 22% from 1,545 units as of June 30, 2025.
●Total consumable cartridges of 106,500 units, up 35% from 78,750 in fiscal 2025.
●502 active customers as of June 30, 2026.
Progress Toward FDA Clearance and U.S. Market Expansion
made substantial progress throughout fiscal 2026 in advancing its FDA 510(k) submission, supporting its planned entry into the multi-billion-dollar U.S. drug screening market beyond current Forensic Use Only settings. The Company’s regulatory program accelerated significantly, underpinned by a series of clinical and technical studies:
●Initiated and completed a clinical cut-off study evaluating codeine detection cut-off levels in 40 adults, advancing the clinical evidence base for the 510(k) program.
●Completed penetration testing, with no major vulnerabilities identified, strengthening the cybersecurity component of the submission package.
●Initiated a multi-site method comparison study, designed to evaluate system accuracy when operated by intended end-users. The study was completed in early fiscal 2027.
●Initiated an interference study examining the impact of everyday substances on the Intelligent Fingerprinting Drug Screening System. The study was completed in early fiscal 2027.
●Initiated precision testing, evaluating reproducibility across varied manufacturing conditions and operating environments. The study was completed in early fiscal 2027, confirming reproducibility across more than 1,600 tests, three production runs, and three independent testing sites.
●Initiated a usability study designed to evaluate how effectively operators could be trained to use the Intelligent Fingerprinting Drug Screening System. The study was completed in early fiscal 2027.
●Initiated validation study for a rapid drug screening cartridge targeting 70% faster results.
●Strengthened the Company’s European intellectual property portfolio with its eighth paten
May 14, 2026 · 100% conf.
1D
-1.39%
$4.05
Act: -0.97%
5D
-13.60%
$3.55
Act: -36.01%
20D
-12.13%
$3.61
Act: -41.61%
2 ex99-1.htm
Exhibit 99.1
Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year
Razor-razorblade
business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales
Nine-month
revenue reaches $3.07 million, up 39% year-over-year, building on record first-half performance
Gross profit margin expands to 50.5% in Q3 and 49.3% for the nine months, improving approximately 800 basis points year-over-year for the nine-month period
NEW YORK, May 13, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal third quarter and nine months ended March 31, 2026, and provided a business update.
“The third quarter marked another period of strong commercial execution and revenue growth,” said Harry Simeonidis, President and CEO at INBS. “Cartridge revenue increased 59% year-over-year and accounted for 66% of Q3 revenue, confirming that customer utilization patterns align with our recurring revenue, razor-razorblade business model. Nine-month revenue of $3.07 million reflects consistent and compounding growth, and the business is continuing to strengthen ahead of important FDA regulatory milestones and our anticipated entry into the multi-billion-dollar U.S. market.”
“Our results this quarter and over the past nine months demonstrate that we are delivering on our core business fundamentals,” said Spiro Sakiris, CFO at INBS. “Q3 gross margin was over 50%, up from 47% a year ago. This growth was driven by operational efficiencies and increased sales volumes. Our value-driven pricing structure has also remained consistent, as customers recognize the efficiency and cost-effectiveness of our fingerprint drug screening technology compared to traditional methods. Our nine-month marketing investment of $1.77 million has been a direct contributor to our 39% revenue growth and successful capital raising of $14.67 million (net of issuance costs), and we are now seeing improved marketing efficiency in Q3, with the quarter’s spend down 42% year-over-year while commercial momentum continues to accelerate.”
Product Revenue Breakdown
Three Months Ended March 31, 2026 (Q3 Fiscal 2026):
●Cartridge sales of $703,538, up 59% year-over-year, representing 66% of Q3 revenue
●Reader sales of $139,407, declined 16% year-over-year, reflecting normal quarterly variability following a strong Q2
●Other sales of $217,857, up 80% year-over-year, representing 21% of Q3 revenue
●Total revenue of $1.06 million, up 46% year-over-year
●Gross profit margin of 50.5%, up from 46.8% in the same period the year prior
●Cash and cash equivalents of $6.86 million at March 31, 2026, compared to $740,371 at December 31, 2025
Nine Months Ended March 31, 2026:
●Cartridge sales of $1.86 million, up 46% year-over-year, representing 61% of nine-month revenue
●Reader sales of $672,839, up 29% year-over-year
●Other sales of $535,942, up 31% year-over-year
●Total revenue of $3.07 million, up 39% year-over-year
●Gross profit margin of 49.3%, up from 41.3% in the same period the year prior
Fiscal Third Quarter and Nine Months Ended March 31, 2026, and Subsequent Highlights
●Gross margin exceeds 50%: Q3 gross profit margin of 50.47%, up from 46.84% in the prior year period, shows the Company’s ability to scale revenue while improving unit economics.
●Cartridge revenue up 59% year-over-year: Cartridge sales of $703,538 represented 66% of Q3 revenue, up from 61% a year ago. The installed base built through prior reader placements is now generating strong, recurring consumable demand.
●Nine-month revenue of $3.07 million: Building on the $2.01 million first-half milestone announced in February 2026, the Company added $1.06 million in revenue in Q3, demonstrating that commercial momentum is sustained and accelerating.
●Other sales surge 80% year-over-year: The 80% year-over-year growth in Q3 other sales signals a broadening product ecosystem and expanding revenue diversification beyond core hardware and consumables.
510(k) regulatory program advancing: The Company continued to make progress on its planned entry into the multi-billion-dollar U.S. drug screening market, including successfully completing penetration testing with no major vulnerabilities identified, completing a clinical cut-off study, and initiating a validation study for the rapid drug screening cartridge targeting 70% faster results.
●New manufacturing partnership: The Company successfully manufactured and shipped its first readers under the new partnership, supporting improved margins and production scalability.
●Bouygues UK partnership: The Company announced a drug-testing rollout with Bouygues UK, part of the global construction group Bouygues Construction, adding a significant new customer in
See how INBS stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "INBS Intelligent Bio Solutions Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.